Vol.56 No.1 January 2008

Clinical efficacies of gatifloxacin(GFLX) for acute rhinosinusitis -Evaluation using clinical scoring

Muneki Hotomi¹⁾, Keiji Fujihara¹⁾, Yoshihumi Uno²⁾, Takao Samukawa³⁾, Kazuya Kinoshita⁴⁾, Masami Kobayashi⁵⁾, Masaki Hayashi⁶⁾, Yasuhiro Hayashi⁷⁾, Takashi Jinnin⁸⁾, Takaaki Kimura⁹⁾, Junichi Yoda¹⁰⁾ and Noboru Yamanaka¹⁾

¹⁾Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, 811-1, Kimiidera, Wakayama, Japan
²⁾UNO ENT Clinic
³⁾Department of Otolaryngology-Head and Neck Surgery, Social Insurance Kinan General Hospital
⁴⁾Department of Otolaryngology-Head and Neck Surgery, Hidaka General Hospital
⁵⁾Department of Otolaryngology-Head and Neck Surgery, Saiseikai Arita Hospital
⁶⁾Department of Otolaryngology-Head and Neck Surgery, Saiseikai Wakayama Hospital
⁷⁾Shirasagidai ENT Clinic
⁸⁾Jinnin ENT Nagusa Clinic
⁹⁾Orange Clinic, Kimura ENT Clinic
¹⁰⁾ENT Clinic JOY

Abstract

We examined the clinical efficacy of gatifloxacin(GFLX) against adult acute rhinosinusitis by disease severity using clinical scoring based on clinical symptoms (rhinorrhea and/or postnasal drip, fever, facial pain and/or forehead pain) and nasal findings (muco-purulent rhinorrhea and/or postnasal drip, serous rhinorrhea and/or postnasal drip, hypertrophy of nasal mucosa, redness of nasal mucosa). Significant relevance was shown between the severity of the disease determined by clinical scoring and experimental definitions. Clinical scoring for adult acute rhinosinusitis will represent the clinical course of the diseases.
Clinical symptoms were significantly improved 7 days after the treatment with GFLX regardless of disease severity. Nasal findings were improved only in moderate and severe cases. The nasal finding of mild acute rhinosinusitis was not changed before and after GFLX treatment. Causative pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis were identified in about 54.0% of the cases and all were dramatically eliminated after treatment.
The total efficacy of GFLX for adult acute rhinosinusitis according to both clinical and bacteriological efficacy was 98% (48 of 49 cases). This study suggested that GFLX may be an effective antimicrobial agent against adult acute rhinosinusitis.

Key word

gatifloxacin, acute rhinosinusitis, clinical effect, clinical score

Received

December 26, 2006

Accepted

September 14, 2007

Jpn. J. Chemother. 56 (1): 7-15, 2008